Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis

F. Carbone; F. Grossi; A. Bonaventura; A. Vecchié; S. Minetti; N. Bardi; E. Elia; A.M. Ansaldo; D. Ferrara; E. Rijavec; M.G. Dal Bello; F. Biello; G. Rossi; M. Tagliamento; A. Alama; S. Coco; P. Spallarossa; F. Dallegri; C. Genova; F. Montecucco

doi:10.1007/s10585-019-09984-z

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis

F. Carbone, F. Grossi, A. Bonaventura, A. Vecchié, S. Minetti, N. Bardi, E. Elia, A.M. Ansaldo, D. Ferrara, E. Rijavec, M.G. Dal Bello, F. Biello, G. Rossi, M. Tagliamento, A. Alama, S. Coco, P. Spallarossa, F. Dallegri, C. Genova, F. Montecucco

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	449-456
Number of pages	8
Journal	Clin. Exp. Metastasis
Volume	36
Issue number	5
DOIs	https://doi.org/10.1007/s10585-019-09984-z
Publication status	Published - 2019

Keywords

Inflammation
Neutrophil
Nivolumab
Non-small cell lung cancer
Osteopontin
C reactive protein
gamma glutamyltransferase
nivolumab
osteopontin
adult
Article
cancer survival
disease severity
enzyme linked immunosorbent assay
female
follow up
gamma glutamyl transferase blood level
human
hypoalbuminemia
immune response
liver metastasis
lymphocyte count
major clinical study
male
metastasis
mortality rate
neutrophil count
non small cell lung cancer
overall survival
protein blood level
treatment response

Access to Document

10.1007/s10585-019-09984-z

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071714126&doi=10.1007%2fs10585-019-09984-z&partnerID=40&md5=d764e8c330434318bf54861c10eff1de

Cite this

Carbone, F., Grossi, F., Bonaventura, A., Vecchié, A., Minetti, S., Bardi, N., Elia, E., Ansaldo, A. M., Ferrara, D., Rijavec, E., Dal Bello, M. G., Biello, F., Rossi, G., Tagliamento, M., Alama, A., Coco, S., Spallarossa, P., Dallegri, F., Genova, C., & Montecucco, F. (2019). Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis. Clin. Exp. Metastasis, 36(5), 449-456. https://doi.org/10.1007/s10585-019-09984-z

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer : Clinical and Experimental Metastasis. / Carbone, F.; Grossi, F.; Bonaventura, A.; Vecchié, A.; Minetti, S.; Bardi, N.; Elia, E.; Ansaldo, A.M.; Ferrara, D.; Rijavec, E.; Dal Bello, M.G.; Biello, F.; Rossi, G.; Tagliamento, M.; Alama, A.; Coco, S.; Spallarossa, P.; Dallegri, F.; Genova, C.; Montecucco, F.

In: Clin. Exp. Metastasis, Vol. 36, No. 5, 2019, p. 449-456.

Research output: Contribution to journal › Article

Carbone, F , Grossi, F, Bonaventura, A, Vecchié, A, Minetti, S, Bardi, N, Elia, E, Ansaldo, AM, Ferrara, D, Rijavec, E , Dal Bello, MG, Biello, F, Rossi, G, Tagliamento, M, Alama, A , Coco, S , Spallarossa, P, Dallegri, F, Genova, C & Montecucco, F 2019, 'Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis', Clin. Exp. Metastasis, vol. 36, no. 5, pp. 449-456. https://doi.org/10.1007/s10585-019-09984-z

Carbone, F. ; Grossi, F. ; Bonaventura, A. ; Vecchié, A. ; Minetti, S. ; Bardi, N. ; Elia, E. ; Ansaldo, A.M. ; Ferrara, D. ; Rijavec, E. ; Dal Bello, M.G. ; Biello, F. ; Rossi, G. ; Tagliamento, M. ; Alama, A. ; Coco, S. ; Spallarossa, P. ; Dallegri, F. ; Genova, C. ; Montecucco, F. / Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer : Clinical and Experimental Metastasis. In: Clin. Exp. Metastasis. 2019 ; Vol. 36, No. 5. pp. 449-456.

@article{cd7d6a08639f48f3844ad7d2577b6a48,

title = "Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis",

keywords = "Inflammation, Neutrophil, Nivolumab, Non-small cell lung cancer, Osteopontin, C reactive protein, gamma glutamyltransferase, nivolumab, osteopontin, adult, Article, cancer survival, disease severity, enzyme linked immunosorbent assay, female, follow up, gamma glutamyl transferase blood level, human, hypoalbuminemia, immune response, liver metastasis, lymphocyte count, major clinical study, male, metastasis, mortality rate, neutrophil count, non small cell lung cancer, overall survival, protein blood level, treatment response",

author = "F. Carbone and F. Grossi and A. Bonaventura and A. Vecchi{\'e} and S. Minetti and N. Bardi and E. Elia and A.M. Ansaldo and D. Ferrara and E. Rijavec and {Dal Bello}, M.G. and F. Biello and G. Rossi and M. Tagliamento and A. Alama and S. Coco and P. Spallarossa and F. Dallegri and C. Genova and F. Montecucco",

note = "Export Date: 30 January 2020 CODEN: CEXMD Correspondence Address: Carbone, F.; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, Italy; email: federico.carbone@unige.it",

year = "2019",

doi = "10.1007/s10585-019-09984-z",

language = "English",

volume = "36",

pages = "449--456",

journal = "Clin. Exp. Metastasis",

issn = "0262-0898",

publisher = "Springer Netherlands",

number = "5",

}

TY - JOUR

T1 - Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

T2 - Clinical and Experimental Metastasis

AU - Carbone, F.

AU - Grossi, F.

AU - Bonaventura, A.

AU - Vecchié, A.

AU - Minetti, S.

AU - Bardi, N.

AU - Elia, E.

AU - Ansaldo, A.M.

AU - Ferrara, D.

AU - Rijavec, E.

AU - Dal Bello, M.G.

AU - Biello, F.

AU - Rossi, G.

AU - Tagliamento, M.

AU - Alama, A.

AU - Coco, S.

AU - Spallarossa, P.

AU - Dallegri, F.

AU - Genova, C.

AU - Montecucco, F.

N1 - Export Date: 30 January 2020 CODEN: CEXMD Correspondence Address: Carbone, F.; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, Italy; email: federico.carbone@unige.it

PY - 2019

Y1 - 2019

KW - Inflammation

KW - Neutrophil

KW - Nivolumab

KW - Non-small cell lung cancer

KW - Osteopontin

KW - C reactive protein

KW - gamma glutamyltransferase

KW - nivolumab

KW - osteopontin

KW - adult

KW - Article

KW - cancer survival

KW - disease severity

KW - enzyme linked immunosorbent assay

KW - female

KW - follow up

KW - gamma glutamyl transferase blood level

KW - human

KW - hypoalbuminemia

KW - immune response

KW - liver metastasis

KW - lymphocyte count

KW - major clinical study

KW - male

KW - metastasis

KW - mortality rate

KW - neutrophil count

KW - non small cell lung cancer

KW - overall survival

KW - protein blood level

KW - treatment response

U2 - 10.1007/s10585-019-09984-z

DO - 10.1007/s10585-019-09984-z

M3 - Article

VL - 36

SP - 449

EP - 456

JO - Clin. Exp. Metastasis

JF - Clin. Exp. Metastasis

SN - 0262-0898

IS - 5

ER -